HORSHAM, PENNSYLVANIA | January 27, 2026 — Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). The approval expands access to a subcutaneous anti-CD38 antibody-based regimen that demonstrated significantly deeper and more durable responses compared with a standard triplet therapy.
Science Significance
From a scientific standpoint, this approval reinforces the role of CD38-targeted immunotherapy as a foundational component of frontline multiple myeloma treatment. The decision is supported by data from the Phase 3 CEPHEUS trial, which showed that adding DARZALEX FASPRO® to VRd significantly improved minimal residual disease (MRD) negativity, depth of response, and progression-free survival (PFS). MRD negativity at a sensitivity of 10⁻⁵—a key marker of deep disease control—was achieved in over half of treated patients, highlighting the regimen’s ability to suppress malignant plasma cells more effectively. These findings underscore how quadruplet regimens can reshape disease biology early in the treatment course, potentially altering long-term outcomes.
Regulatory Significance
Regulatorily, the FDA approval represents a major label expansion for DARZALEX FASPRO®, now marking its twelfth U.S. indication and fifth in the newly diagnosed setting. Importantly, this is the only anti-CD38 antibody-based quadruplet regimen approved across newly diagnosed patients regardless of transplant eligibility, reflecting the FDA’s confidence in the robustness of the clinical data package. The approval further demonstrates the agency’s growing acceptance of MRD negativity as a clinically meaningful endpoint in hematologic malignancies, provided it is supported by durable clinical benefit such as improved PFS. For regulatory and quality professionals, the decision highlights the importance of rigorous GCP-compliant trial design, long-term follow-up, and comprehensive safety monitoring in securing expanded indications.
Business Significance
Advertisement
Commercially, the approval strengthens Johnson & Johnson’s hematology oncology portfolio and further positions DARZALEX FASPRO® as a cornerstone therapy in multiple myeloma. With this expanded frontline indication, the product’s addressable patient population increases significantly, particularly among older or frail patients who are not candidates for transplant. The subcutaneous formulation also offers operational advantages, including shorter administration time and reduced infusion-related burden, which can support broader adoption in community oncology settings. For the company, the approval reinforces long-term lifecycle value while maintaining competitive differentiation in an increasingly crowded myeloma market.
Patients’ Significance
For patients, especially those newly diagnosed with multiple myeloma who cannot undergo transplant, the approval represents a meaningful advancement in standard of care. The D-VRd regimen nearly doubled rates of sustained MRD negativity and significantly reduced the risk of disease progression or death compared with VRd alone. These improvements translate into longer periods of disease control, fewer relapses, and potentially improved quality of life. The availability of a subcutaneous, highly effective frontline regimen may also reduce treatment burden while delivering deeper responses earlier in the disease course.
Policy Significance
At the policy level, this approval reflects broader trends in oncology toward earlier use of combination immunotherapies and acceptance of validated surrogate endpoints to accelerate patient access to transformative treatments. It also aligns with public health priorities aimed at improving outcomes in high-incidence, high-mortality cancers such as multiple myeloma. As payers and health systems evaluate value-based care models, therapies that deliver durable responses and delay disease progression are increasingly viewed as investments that can reduce long-term healthcare costs associated with relapse and subsequent lines of therapy.
The FDA approval of the DARZALEX FASPRO®-based D-VRd quadruplet regimen for transplant-ineligible newly diagnosed multiple myeloma patients marks a pivotal milestone in frontline hematologic cancer care. By combining robust scientific evidence, regulatory rigor, and meaningful patient benefit, the decision further cements DARZALEX FASPRO® as a foundational therapy across the myeloma treatment continuum. For the cGxP.wire audience, this approval exemplifies how high-quality clinical data, compliance with regulatory standards, and innovation in drug delivery converge to advance patient-centered oncology care.
Source: Johnson & Johnson press release
